Sugi Predict

Sugi Predict / Compounds / SCHEMBL935828

SCHEMBL935828

SCHEMBL935828

NC(CC1CCCO1)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ TP53 P04637 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ ALOX12 P18054 1/20 0.44
▸ ANPEP P15144 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ GRIN2D O15399 5/20 0.41
▸ GRIN3B O60391 5/20 0.41
▸ GRIN1 Q05586 5/20 0.41
▸ GRIN2A Q12879 5/20 0.41
▸ GRIN2B Q13224 5/20 0.41
▸ GRIN2C Q14957 5/20 0.41
▸ GRIN3A Q8TCU5 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7366756 1.00 USP2 (0.45) USP2SMN1; SMN2TP53HPGDALOX12
SCHEMBL7886396 1.00 USP2 (0.45) USP2SMN1; SMN2TP53HPGDALOX12
SCHEMBL1711635 1.00 USP2 (0.45) USP2SMN1; SMN2TP53HPGDALOX12
SCHEMBL7887892 1.00 USP2 (0.45) USP2SMN1; SMN2TP53HPGDALOX12
SCHEMBL1711638 1.00 USP2 (0.45) USP2SMN1; SMN2TP53HPGDALOX12
SCHEMBL7880579 1.00 USP2 (0.45) USP2SMN1; SMN2TP53HPGDALOX12
SCHEMBL7888124 1.00 USP2 (0.45) USP2SMN1; SMN2TP53HPGDALOX12
SCHEMBL7888410 1.00 USP2 (0.45) USP2SMN1; SMN2TP53HPGDALOX12
SCHEMBL936034 0.95 GRIN2D (0.43) USP2SMN1; SMN2TP53HPGDALOX12
SCHEMBL20543621 0.85 SMN1; SMN2 (0.45) USP2SMN1; SMN2TP53HPGDALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340574-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2025-11-06 — — US disclosed
EP-4504739-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2025-02-12 — — EP disclosed
WO-2023196429-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-12 — — WO disclosed
WO-2023196429-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-12 — — WO disclosed
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 — — US disclosed
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF RAYZEBIO, INC. 2023-05-25 — — US disclosed
EP-2454229-B1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN RISEN (SHANGHAI) PHARMA TECH CO LTD (CN) 2017-09-13 — — EP disclosed
US-20160220519-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN LU, Jiasheng (CN) 2016-08-04 — — US disclosed
US-20160220519-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN LU, Jiasheng (CN) 2016-08-04 — — US disclosed
US-9233913-B2 Amino acid derivatives for the treatment of neuropathic pain Kong, Xianqi (CA) 2016-01-12 — — US disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 — — EP disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
WO-2010127439-A1 AMMO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2010-11-11 — — WO disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 — — US disclosed
WO-2010029461-A1 HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-03-18 — — WO disclosed
US-20100063063-A1 Substituted Heteroaryls PFIZER INC 2010-03-11 — — US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340574-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B USP2 2740/4885SMN1; SMN2 4787/4885TP53 3585/4885
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 USP2 4188/4885SMN1; SMN2 2392/4885TP53 4199/4885
US-20160220519-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN GAP43, OPRL1, NGF USP2 3892/4885SMN1; SMN2 213/4885TP53 4523/4885
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK USP2 3928/4885SMN1; SMN2 2837/4885TP53 4147/4885
US-20230158179-A1 RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF PAICS, LNPEP, DNPEP USP2 3105/4885SMN1; SMN2 2830/4885TP53 107/4885
US-20100063063-A1 Substituted Heteroaryls GCKR, GCK, GALK1 USP2 3587/4885SMN1; SMN2 3447/4885TP53 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.